Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
Ashok Leyland

Ashok Leyland has invested a sum of Rs. 24.95 crore in TVS Trucks and Buses (TVS Trucks) by way of Equity shares. Consequent to the allotment by the Board of Directors of TVS Trucks today, the Company's shareholding in TVS Trucks is 49.9%, by virtue of which, TVS Trucks has become an associate company.

CEAT

CEAT has been selected as an official partner by Board of Control for Cricket in India (BCCI) to sponsor certain segments of the IPL matches, with an aggregate spend of about Rs 240 crore over five years

DIC India

DIC India announced that the 76th Annual General Meeting (AGM) of the company will be held on 22 March 2024.

Grasim Inds

Grasim Industries has repaid commercial paper of Rs 500 crore on 23 February 2024 (maturity date).

Sanofi India

Sanofi India announced that the Board of Directors of the Company at its meeting held on 23 February 2024, inter alia, have recommended the interim dividend of Rs 50 per equity Share (i.e. 500%) , subject to the approval of the shareholders.

Markobenz Ventur

Podar Knitex will hold a meeting of the Board of Directors of the Company on 27 February 2024.

Lancor Holdings

Lancor Holdings will hold a meeting of the Board of Directors of the Company on 1 March 2024.

Mercury Trade Li

Mercury Trade Links has postponed the meeting of the Board of Directors which was scheduled to be held on 22 February 2024. The meeting will now be held on 26 February 2024.

Ashiana Housing

Ashiana Housing has allotted 560 Un-Secured, Redeemable, Non-Convertible Debentures on Private Placement basis for an amount of Rs. 5.60 crore.

Orchid Pharma

Orchid Pharma has received approval by the United States Food and Drug Administration (USFDA) for its novel invention, ‘Enmetazobactam'. This development comes in close succession to the recent recommendation for approval by the European Medicines Agency (EMA).

Enmetazobactam is the first completely invented-in-India Beta Lactamase Inhibitor. This USFDA approval paves the way for the introduction of Enmetazobactam in the United States, the largest pharmaceutical market in the world. The product is expected to be launched within the next couple of quarters in the US market.

This New Drug Approval (NDA) allows the use of Exblifep (Cefepime and Enmetazobactam) as an injection for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex.

Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA. It is a significant development in addressing the global need for affordable and efficacious drugs to combat Anti-Microbial Resistance (AMR).

<< < 1 2 3 4   > >>